BSI-401

N/A

Report date: 2022/07/01 15:29:28

NME

Base Information

Drug NameBSI-401

Drug Alias NameBSI-401

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionPoly (ADP-Ribose) polymerase 1 inhibitors

TargetsPoly (ADP-Ribose) polymerase 1

Therapy Area/IndicationsPancreatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesBiPar Sciences Inc

China Registration ClassN/A

Active CompaniesN/A

Active IndicationsN/A

Inactive IndicationsPancreatic Neoplasms

ATC CodeN/A